By leveraging real-time data, the model adapts to patients' evolving physiological states, enhancing glucose control and patient safety.<h4>Methods</h4>We used the OhioT1DM dataset (2018 and 2020), which includes 8 weeks of continuous glucose measurements, insulin dosing records, and physical activity data for twelve people with type 1 diabetes. The gene discussed is INS; the disease is type 1 diabetes mellitus.